NeuroMetrix Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

NeuroMetrix şirketinin toplam hissedar öz sermayesi $17.3M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $18.9M ve $1.6M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$16.43m
Eşitlik	US$17.31m
Toplam yükümlülükler	US$1.62m
Toplam varlıklar	US$18.93m

Son finansal sağlık güncellemeleri

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

May 11

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

Jan 19

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Jul 21

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

Jan 27

Recent updates

NeuroMetrix reports Q3 results

Oct 20

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Sep 23

NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M

Jul 21

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

May 11

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

Jan 19

NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation

Sep 09

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Jul 21

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

Jan 27

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NURO 'nin kısa vadeli varlıkları ( $18.5M ) kısa vadeli yükümlülüklerini ( $1.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: NURO şirketinin kısa vadeli varlıkları ( $18.5M ) uzun vadeli yükümlülüklerini ( $28.2K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NURO borçsuzdur.

Borcun Azaltılması: NURO son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: NURO şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: NURO serbest nakit akışı her yıl % 28.4 2.2 yıl yetecek nakit akışına sahip olacaktır.

NeuroMetrix Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

NeuroMetrix Receives Non-Compliance Notice From Nasdaq

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

Recent updates

Second quarter 2024 earnings released: US$0.75 loss per share (vs US$1.56 loss in 2Q 2023)

NeuroMetrix, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$1.67 loss per share (vs US$1.64 loss in 1Q 2023)

NeuroMetrix, Inc. has completed a Follow-on Equity Offering in the amount of $0.692831 million.

NeuroMetrix, Inc., Annual General Meeting, Apr 30, 2024

NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

New major risk - Shareholder dilution

RS Fund Discloses its Views on NeuroMetrix

Full year 2023 earnings released: US$6.08 loss per share (vs US$4.96 loss in FY 2022)

NeuroMetrix, Inc. to Report Q4, 2023 Results on Feb 22, 2024

NeuroMetrix, Inc. Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy

Third quarter 2023 earnings released: US$0.21 loss per share (vs US$0.23 loss in 3Q 2022)

New minor risk - Share price stability

NeuroMetrix, Inc. to Report Q3, 2023 Results on Oct 26, 2023

NeuroMetrix Receives Non-Compliance Notice From Nasdaq

NeuroMetrix, Inc. to Report Q2, 2023 Results on Jul 27, 2023

NeuroMetrix, Inc. Announces Sales Force Expansion for Quell Fibromyalgia

NeuroMetrix, Inc. Announces Presentation of New Clinical Data At the Diabetes UK Meeting

NeuroMetrix, Inc. Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy

First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.14 loss in 1Q 2022)

Full year 2022 earnings released: US$0.62 loss per share (vs US$0.45 loss in FY 2021)

NeuroMetrix, Inc. to Report Q4, 2022 Results on Feb 23, 2023

NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

Insufficient new directors

NeuroMetrix, Inc. to Introduce Quell Fibromyalgia At the American College of Rheumatology 2022 Annual Meeting

NeuroMetrix, Inc. Announces Strategic Launch of Quell Fibromyalgia

Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.12 loss in 3Q 2021)

NeuroMetrix reports Q3 results

NeuroMetrix, Inc. to Report Q3, 2022 Results on Oct 20, 2022

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Neurometrix, Inc. Appoints Jonathan Breck Harmel as National Director of Sales

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.13 loss in 2Q 2021)

NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M

NeuroMetrix, Inc. to Report Q2, 2022 Results on Jul 21, 2022

NeuroMetrix, Inc. Appoints Brad Fluegel to Its Board of Directors, Effective July 1, 2022

NeuroMetrix, Inc. Reports Quell(R) Wearable Neuromodulation Device Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Insufficient new directors

NeuroMetrix, Inc. to Report Q1, 2022 Results on Apr 26, 2022

NeuroMetrix, Inc. Reports That Quell® Wearable Neuromodulator to Be Evaluated in Post-Acute Covid-19 Syndrome

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.068 loss in 3Q 2020)

NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation

Senior VP recently sold US$528k worth of stock

Senior VP recently sold US$271k worth of stock

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.28 loss in 2Q 2020)

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

NeuroMetrix, Inc. Announces Quell Technology

NeuroMetrix Announces Top-Line Results from a Randomized Controlled Trial of Quell for Treatment of Fibromyalgia to be Presented at Two Upcoming Pain Medicine Conferences

First quarter 2021 earnings released: US$0.016 loss per share (vs US$0.45 loss in 1Q 2020)

NeuroMetrix, Inc., Annual General Meeting, Apr 27, 2021

Full year 2020 earnings released: US$0.55 loss per share (vs US$3.90 loss in FY 2019)

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

NeuroMetrix, Inc. to Report Q4, 2020 Results on Jan 28, 2021

New 90-day high: US$3.76

New 90-day high: US$3.05

New 90-day high: US$1.86

Third quarter earnings released

NeuroMetrix, Inc. to Report Q3, 2020 Results on Oct 22, 2020

NeuroMetrix, Inc. Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-The-Counter Pain Relief Device

New 90-day low - US$1.72

NeuroMetrix, Inc. to Report Q2, 2020 Results on Jul 23, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin